Story Poster
Notre Dame Football Recruiting

Top 2022 TE Jack Nickel Loves Notre Dame, Will Be Back

October 13, 2019

Jack Nickel‍ had heard plenty about Notre Dame coming into Saturday’s visit to South Bend for the Irish’s game against USC and it all lived up to the hype.

“I loved it,” the 2022 Georgia tight end told Irish Sports Daily afterward. “The game was awesome.”

The Milton High School standout has early offers from schools like Florida State, Kentucky, Virginia Tech, Vanderbilt and Georgia Tech among others.

He took advantage of the opportunity to imagine what it would be like to play for Notre Dame.

“I look at how the position is used and seeing myself in the atmosphere was great,” said Nickel.

On Saturday night, that meant watching tight end Cole Kmet lead the Irish with six catches for 61 yards and a touchdown.

“I think he’s like their main threat for sure,” Nickel said of Kmet. “He’s going to make a great player in the NFL. I honestly think I could be used in the same way there.”

He also enjoyed the atmosphere inside Notre Dame Stadium for the Irish’s 30-27 win over the Trojans.

“The game was close the entire time, so the fans really got into it throughout the four quarters,” he said.

Nickel took a brief tour of campus, which he called “one of the nicest I’ve seen,” and checked out the Gug as well.

“Also one of the nicest I’ve seen, up there with the best,” he said.

While on campus he had the chance to speak with fellow Georgia prospect, 2021 wide receiver Deion Colzie, who committed to the Irish earlier in the day.

“They were just talking about why they chose Notre Dame over some other schools,” he said of Colzie and his family.

Nickel will be in Tallahassee for Florida State’s game against Miami next month, but also plans on returning to South Bend.

“I’ll definitely be back, I just don’t know when,” said Nickel, who added that he’d welcome the opportunity to spend more time with the Irish staff.

subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.